These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

209 related items for PubMed ID: 15867240

  • 21. Phase I pharmacokinetic and pharmacodynamic study of LAQ824, a hydroxamate histone deacetylase inhibitor with a heat shock protein-90 inhibitory profile, in patients with advanced solid tumors.
    de Bono JS, Kristeleit R, Tolcher A, Fong P, Pacey S, Karavasilis V, Mita M, Shaw H, Workman P, Kaye S, Rowinsky EK, Aherne W, Atadja P, Scott JW, Patnaik A.
    Clin Cancer Res; 2008 Oct 15; 14(20):6663-73. PubMed ID: 18927309
    [Abstract] [Full Text] [Related]

  • 22. Differential protein acetylation induced by novel histone deacetylase inhibitors.
    Glaser KB, Li J, Pease LJ, Staver MJ, Marcotte PA, Guo J, Frey RR, Garland RB, Heyman HR, Wada CK, Vasudevan A, Michaelides MR, Davidsen SK, Curtin ML.
    Biochem Biophys Res Commun; 2004 Dec 17; 325(3):683-90. PubMed ID: 15541343
    [Abstract] [Full Text] [Related]

  • 23. Evaluation of the in vitro and in vivo antitumor activity of histone deacetylase inhibitors for the therapy of retinoblastoma.
    Dalgard CL, Van Quill KR, O'Brien JM.
    Clin Cancer Res; 2008 May 15; 14(10):3113-23. PubMed ID: 18483379
    [Abstract] [Full Text] [Related]

  • 24. Rapid alteration of microRNA levels by histone deacetylase inhibition.
    Scott GK, Mattie MD, Berger CE, Benz SC, Benz CC.
    Cancer Res; 2006 Feb 01; 66(3):1277-81. PubMed ID: 16452179
    [Abstract] [Full Text] [Related]

  • 25. Anti-tumor effect of apicidin on Ishikawa human endometrial cancer cells both in vitro and in vivo by blocking histone deacetylase 3 and 4.
    Ahn MY, Chung HY, Choi WS, Lee BM, Yoon S, Kim HS.
    Int J Oncol; 2010 Jan 01; 36(1):125-31. PubMed ID: 19956841
    [Abstract] [Full Text] [Related]

  • 26. Conformational refinement of hydroxamate-based histone deacetylase inhibitors and exploration of 3-piperidin-3-ylindole analogues of dacinostat (LAQ824).
    Cho YS, Whitehead L, Li J, Chen CH, Jiang L, Vögtle M, Francotte E, Richert P, Wagner T, Traebert M, Lu Q, Cao X, Dumotier B, Fejzo J, Rajan S, Wang P, Yan-Neale Y, Shao W, Atadja P, Shultz M.
    J Med Chem; 2010 Apr 08; 53(7):2952-63. PubMed ID: 20205394
    [Abstract] [Full Text] [Related]

  • 27. Cyclic hydroxamic-acid-containing peptide 31, a potent synthetic histone deacetylase inhibitor with antitumor activity.
    Komatsu Y, Tomizaki KY, Tsukamoto M, Kato T, Nishino N, Sato S, Yamori T, Tsuruo T, Furumai R, Yoshida M, Horinouchi S, Hayashi H.
    Cancer Res; 2001 Jun 01; 61(11):4459-66. PubMed ID: 11389076
    [Abstract] [Full Text] [Related]

  • 28. Potential anti-cancer activity of N-hydroxy-7-(2-naphthylthio) heptanomide (HNHA), a histone deacetylase inhibitor, against breast cancer both in vitro and in vivo.
    Park KC, Kim SW, Park JH, Song EH, Yang JW, Chung HJ, Jung HJ, Suh JS, Kwon HJ, Choi SH.
    Cancer Sci; 2011 Feb 01; 102(2):343-50. PubMed ID: 21159061
    [Abstract] [Full Text] [Related]

  • 29. Abrogation of MAPK and Akt signaling by AEE788 synergistically potentiates histone deacetylase inhibitor-induced apoptosis through reactive oxygen species generation.
    Yu C, Friday BB, Lai JP, McCollum A, Atadja P, Roberts LR, Adjei AA.
    Clin Cancer Res; 2007 Feb 15; 13(4):1140-8. PubMed ID: 17317822
    [Abstract] [Full Text] [Related]

  • 30. Antitumor effect of the histone deacetylase inhibitor LAQ824 in combination with 13-cis-retinoic acid in human malignant melanoma.
    Kato Y, Salumbides BC, Wang XF, Qian DZ, Williams S, Wei Y, Sanni TB, Atadja P, Pili R.
    Mol Cancer Ther; 2007 Jan 15; 6(1):70-81. PubMed ID: 17237267
    [Abstract] [Full Text] [Related]

  • 31. Multiple Molecular pathways explain the anti-proliferative effect of valproic acid on prostate cancer cells in vitro and in vivo.
    Shabbeer S, Kortenhorst MS, Kachhap S, Galloway N, Rodriguez R, Carducci MA.
    Prostate; 2007 Jul 01; 67(10):1099-110. PubMed ID: 17477369
    [Abstract] [Full Text] [Related]

  • 32. Noninvasive magnetic resonance spectroscopic pharmacodynamic markers of a novel histone deacetylase inhibitor, LAQ824, in human colon carcinoma cells and xenografts.
    Chung YL, Troy H, Kristeleit R, Aherne W, Jackson LE, Atadja P, Griffiths JR, Judson IR, Workman P, Leach MO, Beloueche-Babari M.
    Neoplasia; 2008 Apr 01; 10(4):303-13. PubMed ID: 18392140
    [Abstract] [Full Text] [Related]

  • 33. Combination strategy targeting the hypoxia inducible factor-1 alpha with mammalian target of rapamycin and histone deacetylase inhibitors.
    Verheul HM, Salumbides B, Van Erp K, Hammers H, Qian DZ, Sanni T, Atadja P, Pili R.
    Clin Cancer Res; 2008 Jun 01; 14(11):3589-97. PubMed ID: 18519793
    [Abstract] [Full Text] [Related]

  • 34. Discovery and pharmacologic characterization of CP-724,714, a selective ErbB2 tyrosine kinase inhibitor.
    Jani JP, Finn RS, Campbell M, Coleman KG, Connell RD, Currier N, Emerson EO, Floyd E, Harriman S, Kath JC, Morris J, Moyer JD, Pustilnik LR, Rafidi K, Ralston S, Rossi AM, Steyn SJ, Wagner L, Winter SM, Bhattacharya SK.
    Cancer Res; 2007 Oct 15; 67(20):9887-93. PubMed ID: 17942920
    [Abstract] [Full Text] [Related]

  • 35. Destabilization of ERBB2 transcripts by targeting 3' untranslated region messenger RNA associated HuR and histone deacetylase-6.
    Scott GK, Marx C, Berger CE, Saunders LR, Verdin E, Schäfer S, Jung M, Benz CC.
    Mol Cancer Res; 2008 Jul 15; 6(7):1250-8. PubMed ID: 18644987
    [Abstract] [Full Text] [Related]

  • 36. Mechanisms of HDAC inhibitor-induced thrombocytopenia.
    Matsuoka H, Unami A, Fujimura T, Noto T, Takata Y, Yoshizawa K, Mori H, Aramori I, Mutoh S.
    Eur J Pharmacol; 2007 Oct 01; 571(2-3):88-96. PubMed ID: 17628529
    [Abstract] [Full Text] [Related]

  • 37. Encapsulation of the topoisomerase I inhibitor GL147211C in pegylated (STEALTH) liposomes: pharmacokinetics and antitumor activity in HT29 colon tumor xenografts.
    Colbern GT, Dykes DJ, Engbers C, Musterer R, Hiller A, Pegg E, Saville R, Weng S, Luzzio M, Uster P, Amantea M, Working PK.
    Clin Cancer Res; 1998 Dec 01; 4(12):3077-82. PubMed ID: 9865923
    [Abstract] [Full Text] [Related]

  • 38. Anti-inflammatory effect of Trichostatin-A on murine bone marrow-derived macrophages.
    Han SB, Lee JK.
    Arch Pharm Res; 2009 Apr 01; 32(4):613-24. PubMed ID: 19407980
    [Abstract] [Full Text] [Related]

  • 39. In vivo imaging of retinoic acid receptor beta2 transcriptional activation by the histone deacetylase inhibitor MS-275 in retinoid-resistant prostate cancer cells.
    Qian DZ, Ren M, Wei Y, Wang X, van de Geijn F, Rasmussen C, Nakanishi O, Sacchi N, Pili R.
    Prostate; 2005 Jun 15; 64(1):20-8. PubMed ID: 15651062
    [Abstract] [Full Text] [Related]

  • 40. Antitumor activity of suberoylanilide hydroxamic acid against thyroid cancer cell lines in vitro and in vivo.
    Luong QT, O'Kelly J, Braunstein GD, Hershman JM, Koeffler HP.
    Clin Cancer Res; 2006 Sep 15; 12(18):5570-7. PubMed ID: 17000694
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 11.